Clinical outcomes of prompt versus deferred 177Lu-PSMA-617 initiation for metastatic castration-resistant prostate cancer (mCRPC) based on prior androgen receptor pathway inhibitor (ARPI) and taxane ...

A phase 2 single-arm study testing SBRT, adenosine signaling modulation, and immune checkpoint inhibition for men with hormone-sensitive oligometastatic prostate cancer (SBRT-AMICO). This is an ASCO ...

A short course of darolutamide (Nubeqa) enhanced the imaging signal of prostate-specific membrane antigen (PSMA)-PET in a ...

An international group of scientists studying the tendency of intrinsically disordered proteins to form biomolecular condensates report that they have found that the mechanisms involved in ...

A TTUHSC research team led by Srinivas Nandana, Ph.D., (center) and Manisha Tripathi, Ph.D., (left) recently completed a study focused on uncovering the molecular and signaling mechanisms that drive ...

Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced that ...

“After treatment with enzalutamide, PSA levels decline due to potent androgen receptor blockade and cell death,” Armstrong ...

The proportion of patients who discontinued treatment was 30.4% in the darolutamide cohort, 40.8% in the enzalutamide cohort, and 46.0% in the apalutamide cohort. Patients with nonmetastatic ...

ORIC Pharmaceuticals (ORIC) lost ~22% in extended trading after the company reported data from a Phase 1b trial for its ...

MINNEAPOLIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company developing targeted therapies for oncology, today announced that the first patient ...